Experimental cell therapy targets devastating autoimmune diseases that resist standard treatments
NCT ID NCT07470151
Summary
This is an early-stage study testing a new cell therapy called EVM18001 for people with severe, hard-to-treat autoimmune diseases: lupus, scleroderma, and myasthenia gravis. The main goal is to check if the treatment is safe and to find the right dose. Researchers will also look for early signs that it might help control these diseases in 12 participants whose conditions haven't responded well to standard medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union hospital Tongji medical college Huazhong university of science and technology
RECRUITINGWuhan, Hubei, 430022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.